1.1
Vedolizumab is recommended as an option for treating moderately to severely active Crohn's disease only if:
-
a tumour necrosis factor‑alpha inhibitor has failed (that is, the disease has responded inadequately or has lost response to treatment) or
-
a tumour necrosis factor‑alpha inhibitor cannot be tolerated or is contraindicated.
Vedolizumab is recommended only if the company provides it with the discount agreed in the patient access scheme.